Literature DB >> 22934941

Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors.

He Jieyu1, Tu Chao, Li Mengjun, Wang Shalong, Guan Xiaomei, Lin Jianfeng, Li Zhihong.   

Abstract

Nampt/Visfatin/PBEF is a primary, rate-limiting enzyme involved in NAD+ biosynthesis, which serves as a pivotal substance for proteins, and is required for cell growth, survival, DNA replication and repair and energy metabolism. Growing researches have elucidated that it is a pleiotropic protein that functions not only as an enzyme, but also as an adipocytokin, a growth factor, and a cytokine. Additionally, accumulated evidences indicate that Nampt is correlated to various malignant tumors, and complicated mechanisms are proposed to be involved in the carcinogenesis, progression, invasion and metastasis of it, including regulation of energy metabolism and genome instability, promotion of proliferation, angiogenesis, and tumor-promoting inflammation, resistance in cell death and avoidance of immune destruction. APO866 and CHS-828 are recognized inhibitors of Nampt, known to block the intracellular and extracellular NAD+ synthesis pathway. Both of them are currently in clinical trials for the treatment of various malignant tumors and have been shown to represent novel promising antitumor chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22934941     DOI: 10.2174/138161212803582531

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  19 in total

Review 1.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

2.  Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.

Authors:  Xin Yue Wang; Jin Zhi Wang; Lu Gao; Fu Yin Zhang; Qi Wang; Ke Jian Liu; Bin Xiang
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-10       Impact factor: 4.219

3.  High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.

Authors:  Hung-Lung Ke; Hui-Hui Lin; Wei-Ming Li; Ching-Chia Li; Lin-Li Chang; Yi-Chen Lee; Chun-Nung Huang; Wen-Jeng Wu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

4.  Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.

Authors:  Jiwang Chen; Justin R Sysol; Sunit Singla; Shuangping Zhao; Aya Yamamura; Daniela Valdez-Jasso; Taimur Abbasi; Krystyna M Shioura; Sakshi Sahni; Vamsi Reddy; Arvind Sridhar; Hui Gao; Jaime Torres; Sara M Camp; Haiyang Tang; Shui Q Ye; Suzy Comhair; Raed Dweik; Paul Hassoun; Jason X-J Yuan; Joe G N Garcia; Roberto F Machado
Journal:  Circulation       Date:  2017-02-15       Impact factor: 29.690

5.  Crystal structure-based comparison of two NAMPT inhibitors.

Authors:  Sai-Long Zhang; Tian-Ying Xu; Zhen-Lin Yang; Shuo Han; Qiang Zhao; Chao-Yu Miao
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

6.  The NAD(+) salvage pathway modulates cancer cell viability via p73.

Authors:  T Sharif; D-G Ahn; R-Z Liu; E Pringle; E Martell; C Dai; A Nunokawa; M Kwak; D Clements; J P Murphy; C Dean; P Marcato; C McCormick; R Godbout; S A Gujar; P W K Lee
Journal:  Cell Death Differ       Date:  2015-11-20       Impact factor: 15.828

7.  In situ imaging and proteome profiling indicate andrographolide is a highly promiscuous compound.

Authors:  Lin Li; Hadhi Wijaya; Sanjay Samanta; Yulin Lam; Shao Q Yao
Journal:  Sci Rep       Date:  2015-06-24       Impact factor: 4.379

8.  Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.

Authors:  Tian-Ying Xu; Sai-Long Zhang; Guo-Qiang Dong; Xin-Zhu Liu; Xia Wang; Xiao-Qun Lv; Qi-Jun Qian; Ruo-Yu Zhang; Chun-Quan Sheng; Chao-Yu Miao
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

9.  Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.

Authors:  Romana R Gerner; Sophie Macheiner; Herbert Tilg; David Nachbaur; Simon Reider; Kerstin Siegmund; Felix Grabherr; Lisa Mayr; Bernhard Texler; Patrizia Moser; Maria Effenberger; Hubert Schwaighofer; Alexander R Moschen; Brigitte Kircher; Herbert Oberacher; Robert Zeiser
Journal:  Leukemia       Date:  2020-01-23       Impact factor: 11.528

Review 10.  Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.

Authors:  Ambra A Grolla; Cristina Travelli; Armando A Genazzani; Jaswinder K Sethi
Journal:  Br J Pharmacol       Date:  2016-06-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.